Adrian Z. Stecyk

Adrian Z. Stecyk, Chairman and CEO

Mr. Stecyk is a co-Founder, Chairman, and Chief Executive Officer of Griffin Securities, Inc. At Griffin, Mr. Stecyk focuses on the firm's investment banking and advisory activities, working with many new and emerging companies in healthcare, technology and other disruptive categories, both public and private. Prior to entering the financial services industry, Adrian Stecyk served as an engineer with Charles Stark Draper Laboratory, a technology R&D company focused on design, development and deployment of advanced technological solutions for some of the nation's most challenging problems in security, space, healthcare, energy and technology. Mr. Stecyk has a B.S. in Aerospace Engineering and an M.B.A. in Finance from Boston University.  |  direct 212.509.7707

Chrystyna Bedrij

Chrystyna Bedrij, co-Founder and Principal

Chrystyna Bedrij, MBA - Co-Founder and Principal at Griffin Securities with over 25 years of investment experience identifying and working with "change the world" people and businesses on high impact ideas, technologies and products that have the potential to solve challenges, improve humanity's well-being, as well as, create significant value for stakeholders. Chrystyna specializes in business development, strategy, and financing activities that advance companies to key value inflection points and strategic exits, including M & A, collaborations and IPOs. Previously, in 2002, Chrystyna launched and helped build the Griffin Research Department, which today provides in-depth research for leading Technology, Value and Healthcare companies. Chrystyna holds a B.A. in Economics from Vassar College and M.B.A. in Finance from New York University's Leonard N. Stern of Business. FINRA license registra-tions include: Series 24 (Principal); 86/87 (Research Analyst Analysis and Regulations); 7 and 63 (Securities.  |  direct 212.509.7708

Thomas J. McGahren, M.D., J.D.

Thomas J. McGahren, M.D., J.D., Senior Managing Director

Dr. McGahren brings diverse skill sets and expertise to his investment banking and strategic advisory position from his experience as a biotechnology analyst, consultant, attorney, and physician. Prior to Griffin, Tom was a Senior Director and senior biotech analyst at Merrill Lynch. Forbes ranked him the #1 Drugs Analyst in 2008. Prior to Wall Street, Tom was a litigator at the international law firm of Kaye Scholer from 1993 to 2001, where he represented pharmaceutical and biotechnology companies, particularly in patent, FDA, and corporate matters. Tom received his M.D. from the University of Virginia School of Medicine, a J.D. from the University of Texas School of Law, and a B.A. from Colgate University.  |  direct 646.442.4253 |  cell 917.826.8395

© Copyright 2022 , Griffin Securities, Inc. All rights reserved.